microdosing glp 1 GLP-1 is popular, but there's little evidence it works Microdose GLP-1 Protocol

( 10.1001/jama.2022.0078) [DOI] [PMC free article] [PubMed] [Google Scholar] Darpo B, Sager P, MacConell L, Cirincione B, Mitchell M, Han J, Huang W, Malloy J, Schulteis C, Shen L, et al

Sources Healthline: Weight Loss is Often a Losing Battle NIH: Glucagon-like peptide 1 (GLP-1) Cleveland Clinic: GLP-1 Agonists NIH: Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes American Diabetes Association: GLP-1 Receptor in Pancreatic -Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner NIH: GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca2+ channels NIH: Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function FDA: Concern Over Compounded GLP-1 Drugs FDA Label: OZEMPIC (Semaglutide Injection) Medication Guide FDA Label: WEGOVY (Semaglutide Injection) Medication Guide FDA Label: RYBELSUS (Oral Semaglutide) Medication Guide FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide Important Medical Information and Disclaimers Medical Disclaimer This information is for educational use only

That finding deserves emphasis

Extensive research over the past decade has provided evidence that GLP-1 receptor agonists do not appear to increase the risk of pancreatic cancer

They are not meant to treat chronic conditions or provide long-term care

13.0 cm (semaglutide) More patients achieved 25% body weight loss: 31.6% on tirzepatide vs